New heart drug shows promise in early trial

NCT ID NCT05642507

Completed Disease control Sponsor: AnaCardio AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called AC01 in 58 adults with heart failure and reduced pumping ability. The goal was to check safety and how the body processes the drug. Participants received either AC01 or a placebo in increasing doses. The study is complete, but results are not yet public.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Amsterdam University Medical Centre

Amsterdam, 1081 HV, Netherlands
Azienda Sanitaria Universitaria Integrata

Trieste, 34149, Italy
Erasmus Medical Centre

Rotterdam, 3015 GD, Netherlands
Golden Jubilee National Hospital

Glasgow, G81 4DY, United Kingdom
Karolinska University Hospital

Stockholm, 171 76, Sweden
King's College Hospital

London, SE5 9RS, United Kingdom
Maastricht Heart and Vascular Center

Maastricht, 6229 HX, Netherlands
Ninewells Hospital and Medical School

Dundee, DD1 9SY, United Kingdom
Sahlgrenska University Hospital

Gothenburg, 413045, Sweden
Skånes Universitetssjukhus Lund

Lund, 222 42, Sweden
Spedali Civilia di Brescia

Brescia, 25123, Italy
University Medical Center

Utrecht, Netherlands
University Medical Centre Groningen/ICON

Groningen, 9718 GZ, Netherlands
University of Glasgow, Institute of Cardiovascular & Medical Sciences

Glasgow, G12 8QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.